Huperzine A: Is it an effective disease-modifying drug for Alzheimer's disease?

Frontiers in Aging Neuroscience

Volumn 6, Issue AUG, 2014, Pages

  Qian, Zhong Ming ^a   Ke, Ya ^a,b  

^a FUDAN UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Acetylcho linesterase inhibitor; Alzheimer's disease; Disease modifying agent; Huperzine A; Non cholinergic effects

Indexed keywords

AMYLOID PRECURSOR PROTEIN; HUPERZINE A; IRON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NUTRACEUTICAL; PROTEIN KINASE C;

ALZHEIMER DISEASE; APOPTOSIS; CHINA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; NERVE CELL; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SENILE PLAQUE; UPREGULATION;

EID: 84906276463     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00216     Document Type: Review

References (66)

1. Adams, J. P., and Dude, S. M. (2005). Late-phase long-term potentiation: getting to the nucleus. Nat. Rev. Neurosci. 6, 737-743. doi: 10.1038/nrn1749
2. Aloe, L., Rocco, M. L., Branching, P., and Mani, L. (2012). Nerve growth factor: from the early discoveries to the potential clinical use. J. Transl. Med. 10, 239. doi:10.1186/1479-5876-10-239
3. Ayton, S., Lei, P., and Bush, A. I. (2012). Homeostasis in Alzheimer's disease. Free Radic. Biol. Med. 62, 76-89. doi:10.1016/j.freeradbiomed.2012.10.558
4. Cardoso, S. M., Santos, S., Swerdlow, R. H., and Oliveira, C. R. (2001). Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J. 15, 1439-1441.
5. Caricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A. J., Caruso, A., et al. (2004). Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 24, 6021-6027. doi:10.1523/JNEUROSCI.1381-04.2004
6. Cattaneo, A., and Calissano, P. (2012). Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis. Mol. Neurobiol. 46, 588-604. doi:10.1007/s12035-012-8310-9
7. Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398. doi:10.1038/nrd2896
8. De Ferrari, G. V., Chacon, M. A., Barria, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., et al. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8, 195-208. doi:10.1038/sj.mp.4001208
9. Emilien, G., Beyreuther, K., Masters, C. L., and Maloteaux, J. M. (2000). Prospects for pharmacological intervention in Alzheimer disease. Arch. Neurol. 57, 454-459. doi:10.1001/archneur.57.4.454
10. Farias, G. G., Godoy, J. A., Vazquez, M. C., Adani, R., Meshulam, H., Avila, J., et al. (2005). The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 18, 176-183. doi:10.1016/j.nbd.2004.09.012
11. Fischer, W., Wictorin, K., Bjorklund, A., Williams, L. R., Varon, S., and Gage, F. H. (1987). Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329, 65-68. doi:10.1038/329065a0
12. Fu, L. M., and Li, J. T. (2011). A systematic review of single Chinese herbs for Alzheimer's disease treatment. Evid. Based Complement. Alternat. Med. 2011, 640284. doi:10.1093/ecam/nep136
13. Gao, X., and Tang, X. C. (2006). Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J. Neurosci. Res. 83, 1048-1057. doi:10.1002/jnr.20791
14. Gao, X., Zheng, C. Y., Yang, L., Tang, X. C., and Zhang, H. Y. (2009). Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic. Biol. Med. 46, 1454-1462. doi:10.1016/j.freeradbiomed.2009.02.028
15. Gordon, R. K., Nigam, S. V., Weitz, J. A., Dave, J. R., Doctor, B. P., and Ved, H. S. (2001). The NMDA receptor ion channel: a site for binding of huperzine A. J. Appl. Toxicol. 21(Suppl. 1), S47-S51. doi:10.1002/jat.805
16. Howes, M. J., and Perry, E. (2011). The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 28, 439-468. doi:10.2165/11591310-000000000-00000
17. Huang, E. J., and Reichard, L. F. (2003). TRK receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609-642. doi:10.1146/annurev.biochem.72.121801.161629
18. Huang, X. T., Qian, Z. M., He, X., Gong, Q., Wu, K. C., Jiang, L. R., et al. (2014). Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease. Neurobiol. Aging 35, 1045-1054. doi:10.1016/j.neurobiolaging.2013.11.004
19. Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295. doi:10.1038/nm.2613
20. Liu, M. Y., and Liu, H. C. (1995). Intelligence promoting Chinese materia medica. [Article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 15, 59-61.
21. Ma, X., Tan, C., Zhu, D., Gang, D. R., and Xiao, P. (2007). Huperzine A from Huperzia species - an ethnopharmacolgical review. J. Ethnopharmacol. 113, 15-34. doi:10.1016/j.jep.2007.05.030
22. Maeda, J., Zhang, M. R., Okauchi, T., Ji, B., Ono, M., Hattori, S., et al. (2011). In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 31, 4720-4730. doi:10.1523/JNEUROSCI.3076-10.2011
23. Martin, S. J., Grimwood, P. D., and Morris, R. G. (2000). Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 23, 649-711. doi:10.1146/annurev.neuro.23.1.649
24. Marx, J. (2000). Alzheimer's congress. Drug shows promise for advanced disease. Science 289, 375-377. doi:10.1126/science.289.5478.375b
25. Orhan, I. E., Orhan, G., and Gurkas, E. (2011). An overview on natural cholinesterase inhibitors - a multi-targeted drug class - and their mass production. Mini Rev. Med. Chem. 11, 836-842. doi:10.2174/138955711796575434
26. Pei, J. J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., et al. (1999). Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019. doi:10.1097/00005072-199909000-00011
27. Qian, Z. M., and Shen, X. (2001). Brain iron transport and neurodegeneration. Trends Mol. Med. 7, 103-110. doi:10.1016/S1471-4914(00)01910-9
28. Qian, Z. M., Wang, Q., and Pu, Y. (1997). Brain iron and neurological disorders. Chin. Med. J. 110, 455-458.
29. Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., et al. (2011). A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76, 1389-1394. doi:10.1212/WNL.0b013e318216eb7b
30. Rao, V. R., and Finkbeiner, S. (2007). NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci. 30, 284-291. doi:10.1016/j.tins.2007.03.012
31. Ratia, M., Giménez-Llort, L., Camps, P., Muñoz-Torrero, D., Pérez, B., Clos, M. V., et al. (2013). Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD). Neurodegener. Dis. 11, 129-140. doi:10.1159/000336427
32. Reddy, P. H., and Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14, 45-53. doi:10.1016/j.molmed.2007.12.002
33. Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J. R., and Bigl, V. (1998). The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56, 541-569. doi:10.1016/S0301-0082(98)00044-6
34. Saille, C., Marin, P., Martinou, J. C., Nicole, A., London, J., and Ceballos-Picot, I. (1999). Transgenic murine cortical neurons expressing human Bcl-2 exhibit increased resistance to amyloid beta-peptide neurotoxicity. Neuroscience 92, 1455-1463. doi:10.1016/S0306-4522(99)00089-5
35. Scott, S. A., Mufson, E. J., Weingartner, J. A., Skau, K. A., and Crutcher, K. A. (1995). Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15, 6213-6221.
36. Shang, Y. Z., Ye, J. W., and Tang, X. C. (1999). Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats. Zhongguo Yao Li Xue Bao 20, 824-828.
37. Silva, D. F., Selfridge, J. E., Lu, J. H., Lezi, E., Cardoso, S. M., and Swerdlow, R. H. (2012). Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv. Pharmacol. 64, 83-126. doi:10.1016/B978-0-12-394816-8.00003-9
38. Skolnick, A. A. (1997). Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 277, 776. doi:10.1001/jama.1997.03540340010004
39. Smith, M. A., Zhu, X., Tabaton, M., Liu, G., McKeel, D. W. Jr., Cohen, M. L., et al. (2010). Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19, 363-372. doi:10.3233/JAD-2010-1239
40. Sucher, N. J., Awobuluyi, M., Choi, Y. B., and Lipton, S. A. (1996). NMDA receptors: from genes to channels. Trends Pharmacol. Sci. 17, 348-355. doi:10.1016/S0165-6147(96)10046-8
41. Tang, L. L., Wang, R., and Tang, X. C. (2005). Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. Acta Pharmacol. Sin. 26, 673-678. doi:10.1111/j.1745-7254.2005.00130.x
42. Tuszynski, M. H., Sang, H., Yoshida, K., and Gage, F. H. (1991). Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. 30, 625-636. doi:10.1002/ana.410300502
43. Wang, C. Y., Zheng, W., Wang, T., Xie, J. W., Wang, S. L., Zhao, B. L., et al. (2011). Huperzine A activates Wnt/ß-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology 36, 1073-1089. doi:10.1038/npp.2010.245
44. Wang, L. M., Han, Y. F., and Tang, X. C. (2000). Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur. J. Pharmacol. 398, 65-72. doi:10.1016/S0014-2999(00)00291-0
45. Wang, R., Xiao, X. Q., and Tang, X. C. (2001a). Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport 12, 2629-2634. doi:10.1097/00001756-200108280-00009
46. Wang, R., Zhang, H. Y., and Tang, X. C. (2001b). Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur. J. Pharmacol. 421, 149-156. doi:10.1016/S0014-2999(01)01030-5
47. Wang, X. D., Zhang, J. M., Yang, H. H., and Hu, G. Y. (1999). Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol. Sin. 20, 31-35.
48. Wang, Y. E., Yue, D. X., and Tang, X. C. (1986). Anti-cholinesterase activity of huperzine A. [Article in Chinese]. Zhongguo Yao Li Xue Bao 7, 110-113.
49. Wang, Z. F., Tang, L. L., Yan, H., Wang, Y. J., and Tang, X. C. (2006). Effects of huperzine A on memory deficits and neurotrophic factors production after in mice. Pharmacol. Biochem. Behav. 83, 603-611. doi:10.1016/j.pbb.2006.03.027
50. Xiao, X. Q., Wang, R., Han, Y. F., and Tang, X. C. (2000a). Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci. Lett. 286, 155-158. doi:10.1016/S0304-3940(00)01088-0
51. Xiao, X. Q., Wang, R., and Tang, X. C. (2000b). Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J. Neurosci. Res. 61, 564-569. doi:10.1002/1097-4547(20000901)61:5<564::AID-JNR11>3.3.CO;2-O
52. Xiao, X. Q., Zhang, H. Y., and Tang, X. C. (2002). Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J. Neurosci. Res. 67, 30-36. doi:10.1002/jnr.10075
53. Xing, S. H., Zhu, C. X., Zhang, R., and An, L. (2014). Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid. Based Complement Alternat. Med. 2014, 363985. doi:10.1155/2014/363985
54. Yang, G., Wang, Y., Tian, J., and Liu, J. P. (2014). Huperzine a for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE 8:e74916. doi:10.1371/journal.pone.0074916
55. Yang, L., Ye, C. Y., Huang, X. T., Tang, X. C., and Zhang, H. Y. (2012). Decreased accumulation of subcellular amyloid-beta with improved mitochondrial function mediates the neuroprotective effect of huperzine A. J. Alzheimers Dis. 31, 131-142. doi:10.3233/JAD-2012-120274
56. Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., and Brinton, R. D. (2011). Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Aspects Med. 32, 247-257. doi:10.1016/j.mam.2011.10.005
57. Zangara, A. (2003). The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 75, 675-686. doi:10.1016/S0091-3057(03)00111-4
58. Zhang, H. Y., Liang, Y. Q., Tang, X. C., He, X. C., and Bai, D. L. (2002a). Stereoselectivities of enantiomers of huperzine A in protection against amyloid 25-35-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci. Lett. 317, 143-146. doi:10.1016/S0304-3940(01)02437-5
59. Zhang, Y. H., Zhao, X. Y., Chen, X. Q., Wang, Y., Yang, H. H., and Hu, G. Y. (2002b). Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex. Neurosci. Lett. 319, 107-110. doi:10.1016/S0304-3940(01)02565-4
60. Zhang, H. Y., Yan, H., and Tang, X. C. (2004). Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci. Lett. 360, 21-24. doi:10.1016/j.neulet.2004.01.055
61. Zhang, J. M., and Hu, G. Y. (2001). Huperzine A, a nootropic alkaloid, inhibits N-methyl-d-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience 105, 663-669. doi:10.1016/S0306-4522(01)00206-8
62. Zhang, Z. H., Xi, G. M., Li, W. C., Ling, H. Y., Qu, P., and Fang, X. B. (2010). Cyclic-AMP response element binding protein and tau are involved in the neuroprotective mechanisms of nerve growth factor during focal cerebral ischemia/reperfusion in rats. J. Clin. Neurosci. 17, 353-356. doi:10.1016/j.jocn.2009.07.086
63. Zhao, L., Qian, Z. M., Zhang, C., Wing, H. Y., Du, F., and Ya, K. (2008). Amyloid beta-peptide 31-35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. Aging Cell 7, 47-57. doi:10.1111/j.1474-9726.2007.00352.x
64. Zhao, L., Zhao, S. T., Qian, Z. M., Zhang, C., Wu, X. M., Du, F., et al. (2009). Activation of group III metabotropic glutamate receptor reduces intracellular calcium in beta-amyloid peptide [31-35]-treated cortical neurons. Neurotox. Res. 16, 174-183. doi:10.1007/s12640-009-9068-3
65. Zhu, X., Raina, A. K., Perry, G., and Smith, M. A. (2004). Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3, 219-226. doi:10.1016/S1474-4422(04)00707-0
66. Zhu, X. D., and Giacobini, E. (1995). Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines. J. Neurosci. Res. 41, 828-835. doi:10.1002/jnr.490410613